Veradermics (MANE) Cash from Operations (2025 - 2026)

Veradermics posted quarterly Cash from Operations of 21168000.0 for Q1 2026, down 58.95% year-on-year from 51572311.75 in Q1 2025, and down 58.95% on a QoQ basis from 13317000.0 in Q1 2025.

Veradermics (MANE) has 2 years of Cash from Operations data on file, last reported at 21168000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -1.67 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 70.50 Mn
10 Veradermics 2.29 Bn 2.29 Bn - -21.17 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -21.17 Mn
Mar 31, 2026 -21.17 Mn
Mar 31, 2025 -13.32 Mn
Mar 31, 2025 -13.32 Mn